Cancers, Vol. 12, Pages 308: Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature —“Are We There Yet?”

Cancers, Vol. 12, Pages 308: Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—“Are We There Yet?” Cancers doi: 10.3390/cancers12020308 Authors: Lamb Sim McCormack Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research

Related Links:

Abstract AarF domain containing kinase 5 (ADCK5) is a member of an atypical kinase family and overexpressed in many carcinomas including lung cancer, while the function of this protein has not been elucidated. Here we investigated the mechanism of ADCK5 involved in regulating invasion and migration of lung cancer cells, and showed that ADCK5 might regulate the expression of tumor oncogene human pituitary tumor transforming gene-1 (PTTG1) by phosphorylating transcription factor SOX9, therefore enhancing the migration and invasion capabilities of lung cancer cells. Mutagenesis of potential serine phosphorylation sit...
Source: Experimental Cell Research - Category: Cytology Authors: Tags: Exp Cell Res Source Type: research
CONCLUSIONS: The present study identified hub genes and pathways in HCC that may be potential targets for diagnosis, treatment and prognostic prediction. PMID: 32200915 [PubMed - in process]
Source: The American Journal of the Medical Sciences - Category: General Medicine Authors: Tags: Am J Med Sci Source Type: research
Authors: Chen FF, Zhang SR, Peng H, Chen YZ, Cui XB Abstract The main purpose of the present study was to recognize the integrative genomics analysis of hub genes and their relationship with prognosis and signaling pathways in esophageal squamous cell carcinoma (ESCC). The mRNA gene expression profile data of GSE38129 were downloaded from the Gene Expression Omnibus database, which included 30 ESCC and 30 normal tissue samples. The differentially expressed genes (DEGs) between ESCC and normal samples were identified using the GEO2R tool. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pat...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Authors: Ma K, Sun X, Ma L, Zhang S Abstract Objectives.: The purpose of this study was to investigate serum pituitary tumor transforming gene (PTTG1) expression in laryngeal carcinoma and its relationship with the clinical pathological characteristics and prognosis. Methods.: Expression of serum PTTG1 was measured by enzyme-linked immunosorbent assay in 110 patients with laryngeal carcinoma and 60 patients with vocal cord polyps. Expression of the serum PTTG1 levels relationship with the clinicopathological characteristics and prognosis were analyzed. Results.: In laryngeal carcinoma patients' serum, the P...
Source: Clinical and Experimental Otorhinolaryngology - Category: ENT & OMF Tags: Clin Exp Otorhinolaryngol Source Type: research
Our data suggest that pituitary tumor transforming gene 1 (PTTG1) plays a vital role in inflammation ‐related hepatocellular carcinoma (HCC) via c‐myc induction and that PTTG1 may be a potential therapeutic target for HCC. AbstractHepatocellular carcinoma (HCC) is a malignant disease caused by a variety of factors. However, the genomic and molecular aberrations in HCC are largely unknown. Herein,pituitary tumor transforming gene 1 (PTTG1) was discovered as a potential inflammation ‐related oncogene in HCC, and its functions and molecular mechanisms were investigated. mRNA expression microarray, real‐time polymerase...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conditions:   Pituitary;   Pituitary Tumor;   Pituitary Carcinoma;   Pituitary Cancer Interventions:   Drug: Ipilimumab;   Drug: Nivolumab Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: - Category: Research Source Type: clinical trials
ConclusionsIn this large cancer-database-based analysis we observed improved overall survival in patients harboring PC in the years following the introduction of TMZ.
Source: Endocrine - Category: Endocrinology Source Type: research
Authors: Harada K, Yasuda M, Hasegawa K, Yamazaki Y, Sasano H, Otsuka F Abstract Adrenocortical carcinoma (ACC) is a rare malignancy arising from adrenocortical parenchymal cells. Myxoid ACC is one of the newly identified, rare, but important histological variants of ACC, characterized by the presence of abundant extracellular Alcian Blue-positive myxoid material. Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant cancer predisposition syndrome, and the incidence of ACC in MEN1 patients has been reported to be between 1.4% and 6%. Here, we report the case of a 68-year-old Japanese woman harboring t...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Editor: V. Dimov, M.D., Assistant Professor at University of ChicagoDisseminated Cryptococcosis in a CLL patient. NEJM, 05/2014.Leukemia cutis. Lancet, 10/2012.Biliary ileus. Lancet, 07/2012.Corneal snowflakes due to IgG-kappa multiple myeloma. Lancet, 08/2012.Splenic Spirals due to hepatoblastoma. NEJM, 06/2012.Hypertrophic Pulmonary Osteoarthropathy and Tripe Palms due to lung cancer. NEJM, 01/2012.Metastasis of Renal-Cell Carcinoma. NEJM, 10/2011.Amelanotic choroidal melanoma. Lancet, 03/2011.Retroperitoneal liposarcoma with lamellar bone inside.A painful cranial bulge. Lancet, 05/2011.Splenic Calcification in sick...
Source: Clinical Cases and Images - Category: General Medicine Tags: Hematology Images Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Pituitary Tumor